about
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm MeetingBiosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry.Biotherapeutic bioanalysis: a multi-indication case study review.Biosimilars and market access: a question of comparability and costs?Introduction of biosimilar insulins in Europe.Assessing switchability for biosimilar products: modelling approaches applied to children's growth.Biosimilar growth hormone.
P2860
Q34377347-A7CB7874-0D91-400D-8966-2B88091449EEQ36564693-2EEE9569-8CF6-4D9D-98BC-189B1BB130F8Q37854629-CE3E56BB-8B1B-4959-82B7-40B280CB854FQ37976334-59CE820B-B99D-49F4-8ECA-7F12F08FC9ECQ39368850-C9F085CA-AC8D-48FD-9103-84E102DDFCC2Q40924057-F8FAD98E-CBB8-4726-9535-D7CFFB7653CBQ45254568-42021A9E-7B29-46CE-BAD6-CBD101B16FDC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biosimilars: controversies as illustrated by rhGH.
@en
Biosimilars: controversies as illustrated by rhGH.
@nl
type
label
Biosimilars: controversies as illustrated by rhGH.
@en
Biosimilars: controversies as illustrated by rhGH.
@nl
prefLabel
Biosimilars: controversies as illustrated by rhGH.
@en
Biosimilars: controversies as illustrated by rhGH.
@nl
P2093
P1476
Biosimilars: controversies as illustrated by rhGH
@en
P2093
Feyza Darendeliler
Ioana Micle
Jirina Zapletalová
Michael B Ranke
Miklós Góth
Natalia N Volevodz
Stanislava Kolouskova
Valentina Peterkova
P304
P356
10.1185/03007991003719642
P407
P577
2010-05-01T00:00:00Z